Evidence map›Paper›PMID 42095929›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

Large fiber contribution to symptoms in chemotherapy-induced peripheral neuropathy in cancer survivors.

Jon D Levine, Bruce A Cooper, Gary Abrams, Carolyn Harris, Steven M Paul, Yvette P Conley, Marilyn J Hammer, Christine Miaskowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jon D LevineSchool of Medicine, University of California, San Francisco, CA, USA.
Bruce A CooperSchool of Nursing, University of California, San Francisco, CA, USA.
Gary AbramsSchool of Medicine, University of California, San Francisco, CA, USA.
Carolyn HarrisSchool of Nursing, University of California, San Francisco, CA, USA.
Steven M PaulSchool of Nursing, University of California, San Francisco, CA, USA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, PA, USA.
Marilyn J HammerPhyllis F. Cantor Center, Dana Farber Cancer Institute, Boston, MA, USA.
Christine MiaskowskiSchool of Nursing, University of California, San Francisco, CA, USA. chris.miaskowski@ucsf.edu.

Funding

Characterization of and Treatment for Chemotherapy NeuropathyR01CA151692 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2011 to 2015
$6.4M
CCR NIH HHS CA151692NCI NIH HHS R01 CA151692
6 · The paper itself

Abstract

purposeChemotherapy-induced peripheral neuropathy (CIPN) is associated with a large amount of interindividual variability in signs and symptoms. The purposes were to use latent profile analysis to identify subgroups of survivors with distinct lower extremity (LE) loss-of-function CIPN profiles; evaluate for differences in demographic, clinical, and pain characteristics between the profiles and characteristics associated with membership in the more severe profile; and examine relationships between the profiles and measures of large fiber loss and C-tactile fiber function.

methodsLE loss-of-function CIPN profiles were created using measures of worst pain, loss of light touch sensation, loss of cold sensation, loss of pain sensation, vibration threshold, and two balance measures.

resultsOf the 405 survivors evaluated, two distinct profiles were identified: less severe loss of LE function (76.5%) and more severe loss of LE function (23.5%). Risk factors for membership in the more severe profile included being older, male, and having lower functional status. In terms of the loss of large fiber function, survivors in the more severe class had four more sites on average that lost light touch sensation; their vibration thresholds were 1.5 times higher; and their ratings of numbness were significantly higher. For C-tactile fiber function, significant between-group differences were found in survivors' ratings of the severity of sensitive skin and unpleasantness.

conclusionsFindings suggest that distinct "CIPN phenotypes" can be identified in cancer survivors. Detailed phenotyping and molecular characterization of various CIPN phenotypes will lead to the development and testing of targeted and personalized interventions.

Indexed as

Antineoplastic AgentsCancer SurvivorsNeoplasmsPeripheral Nervous System DiseasesAdultAgedAge FactorsFemaleHumansLower ExtremityMaleMiddle AgedPainRisk FactorsSeverity of Illness IndexSex FactorsAntineoplastic AgentsAffective touchBalanceChemotherapy-induced peripheral neuropathyC-Tactile afferentsLarge fiber functionNumbnessPainTouch sensationVibration

Identifiers

PMID42095929
PMCPMC13152890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.